Kubota Pharmaceutical Holdings Co., Ltd.

Tokyo Stock Exchange 4596.T

Kubota Pharmaceutical Holdings Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 0.97

Kubota Pharmaceutical Holdings Co., Ltd. Price to Book Ratio (P/B) is 0.97 on January 14, 2025, a -32.77% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Kubota Pharmaceutical Holdings Co., Ltd. 52-week high Price to Book Ratio (P/B) is 1.65 on August 01, 2024, which is 69.91% above the current Price to Book Ratio (P/B).
  • Kubota Pharmaceutical Holdings Co., Ltd. 52-week low Price to Book Ratio (P/B) is 0.94 on December 24, 2024, which is -3.38% below the current Price to Book Ratio (P/B).
  • Kubota Pharmaceutical Holdings Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 1.25.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Tokyo Stock Exchange: 4596.T

Kubota Pharmaceutical Holdings Co., Ltd.

CEO Dr. Ryo Kubota M.D., Ph.D.
IPO Date Dec. 6, 2016
Location Japan
Headquarters 3-7-1 Kasumigaseki
Employees 12
Sector Health Care
Industries
Pharmaceuticals
Description

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email